SPRR2A and neoplasm: Ultimately, we hope this approach will lead to in vivo persistence of adoptively transferred 4H11-28z/fIL-12/EFGRt T cells allowing for anti-tumor efficacy and further modulation of tumor microenvironment, such that the patient develops increased progression-free survival.